OncoMatch/Clinical Trials/NCT05855200
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
Is NCT05855200 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Dostarlimab and CAPEOX for colonic neoplasms.
Treatment: Dostarlimab · CAPEOX · FOLFOX — The primary purpose of this study is to evaluate the efficacy of perioperative dostarlimab compared with standard of care (SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instability high (dMMR/MSI-H) colon cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Disease stage
Required: Stage T4N0, III
Excluded: Stage DISTANT METASTATIC DISEASE
resectable colon adenocarcinoma defined as clinically T4N0 or Stage III; Has distant metastatic disease [excluded]
Prior therapy
Cannot have received: chemotherapy
Has received prior medical therapy (chemotherapy, immunotherapy, biologic, or targeted therapy), radiation therapy or surgery for management of the current diagnosis of colon cancer
Cannot have received: immunotherapy
Has received prior medical therapy (chemotherapy, immunotherapy, biologic, or targeted therapy), radiation therapy or surgery for management of the current diagnosis of colon cancer
Cannot have received: biologic
Has received prior medical therapy (chemotherapy, immunotherapy, biologic, or targeted therapy), radiation therapy or surgery for management of the current diagnosis of colon cancer
Cannot have received: targeted therapy
Has received prior medical therapy (chemotherapy, immunotherapy, biologic, or targeted therapy), radiation therapy or surgery for management of the current diagnosis of colon cancer
Cannot have received: radiation therapy
Has received prior medical therapy (chemotherapy, immunotherapy, biologic, or targeted therapy), radiation therapy or surgery for management of the current diagnosis of colon cancer
Cannot have received: surgery
Has received prior medical therapy (chemotherapy, immunotherapy, biologic, or targeted therapy), radiation therapy or surgery for management of the current diagnosis of colon cancer
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- GSK Investigational Site · Tucson, Arizona
- GSK Investigational Site · Los Angeles, California
- GSK Investigational Site · New Haven, Connecticut
- GSK Investigational Site · Washington D.C., District of Columbia
- GSK Investigational Site · Deerfield Beach, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05855200 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage T4N0 or III is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify